United Therapeutics Corporation
UTHR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.07 | -2.35 | 1.65 | -4.83 |
| FCF Yield | 1.91% | 1.00% | 2.79% | 1.60% |
| EV / EBITDA | 36.77 | 26.02 | 31.72 | 34.31 |
| Quality | ||||
| ROIC | 4.41% | 3.74% | 4.03% | 3.92% |
| Gross Margin | 87.38% | 89.03% | 88.36% | 89.69% |
| Cash Conversion Ratio | 1.66 | 0.62 | 1.43 | 1.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.38% | 13.39% | 14.76% | 14.11% |
| Free Cash Flow Growth | 171.51% | -66.48% | 51.79% | -15.36% |
| Safety | ||||
| Net Debt / EBITDA | -2.90 | -3.65 | -4.44 | -3.29 |
| Interest Coverage | 129.50 | 49.93 | 62.75 | 45.28 |
| Efficiency | ||||
| Inventory Turnover | 0.57 | 0.52 | 0.56 | 0.48 |
| Cash Conversion Cycle | -226.50 | -227.25 | -159.67 | 214.28 |